The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pre-emptive skin toxicity treatment for anti-EGFR drugs: Evaluation of efficacy of skin moisturizers and limecicline—A phase II study.
R. Grande
No relevant relationships to disclose
F. Narducci
No relevant relationships to disclose
G. Mansueto
No relevant relationships to disclose
D. Gemma
No relevant relationships to disclose
I. Sperduti
No relevant relationships to disclose
S. Bianchetti
No relevant relationships to disclose
F. Angelini
No relevant relationships to disclose
G. Trombetta
No relevant relationships to disclose
T. Gamucci
No relevant relationships to disclose